Photodynamic therapy reduces cell viability, migration and triggers necroptosis in prostate tumor cells. (2023)

Peer-Reviewed Study · de Melo Gomes LC; de Oliveira Cunha AB; Peixoto LFF; Zanon RG; Botelho FV; Silva MJB; Pinto-Fochi ME; Góes RM; de Paoli F; Ribeiro DL · March 3, 2023

de Melo Gomes LC, 2023-03-03: Brazilian study of methylene blue photodynamic therapy in PC3 prostate cancer cells: viability and migration reduced, with necroptosis accompanied by autophagy as the primary mode of cell death – the abstract states apoptosis was not the primary mode, not that apoptosis was absent.

However, because MB-PDT did not significantly increase the levels of active caspase-3 and BCL-2, apoptosis was not the primary mode of cell death.

de Melo Gomes LC, 2023-03-03: Brazilian study of methylene blue photodynamic therapy in PC3 prostate cancer cells: viability and migration reduced, with necroptosis accompanied by autophagy as the primary mode of cell death – the abstract states apoptosis was not the primary mode, not that apoptosis was absent. C2/C3 de Melo Gomes 2023. Study type: in vitro cell-line study (human PC3 prostate adenocarcinoma). Country: Brazil (Universidade Estadual Paulista and Universidade Federal de Uberlandia). Dose: methylene blue 25 uM for 30 min; laser 660 nm, 100 mW, 100 J/cm2; endpoints at 24 h. Funder: FAPEMIG (APQ-01807-17). Conflicts: 'The authors have no conflict of interest.' Comparator: DMEM control, laser-only and MB-only (dark) arms. Products: methylene blue, supplier not stated. Also filed as MTG-018, MTM-17, MTN-02 (claims C1, C2, C3). Study type: lab.